<DOC>
	<DOCNO>NCT00605215</DOCNO>
	<brief_summary>The study aim compare effect daily oral treatment laquinimod capsule 0.6 mg effect placebo capsule ( capsule contain active medication ) well effect exist MS injectable drug : Interferon β-1a ( Avonex® ) .</brief_summary>
	<brief_title>BRAVO Study : Laquinimod Double Blind Placebo Controlled Study RRMS Patients With Rater Blinded Reference Arm Interferon β-1a ( Avonex® )</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>1 . Subjects must confirm documented MS diagnosis define Revised McDonald criterion [ Ann Neurol 2005 : 58:840846 ] , relapsingremitting disease course . 2 . Subjects must ambulatory convert Kurtzke EDSS score 05.5 . 3 . Subjects must stable neurological condition screening ( month 1 ) baseline visit ( month 0 ) . 4 . Subjects must experience one following : 5 . At least one document relapse 12 month prior screen 6 . At least two documented relapse 24 month prior screen 7 . One document relapse 12 24 month prior screen least one document T1Gd enhance lesion MRI perform within 12 month prior screen . 8 . Subjects must 18 55 year age , inclusive . 9 . Subjects must disease duration least 6 month ( first symptom ) prior screen . 10 . Women childbearing potential must practice 2 acceptable method birth control [ acceptable method birth control study include : surgical sterilization , intrauterine device , oral contraceptive , contraceptive patch , longacting injectable contraceptive , partner 's vasectomy doublebarrier method ( condom diaphragm spermicide ) ] . 11 . Subjects must willing able comply protocol requirement duration study . . 12 . An onset relapse treatment corticosteroid ( intravenous [ iv ] , intramuscular [ im ] and/or per o [ po ] ) ACTH month 1 ( screen ) 0 ( baseline ) . 13 . Use experimental investigational drug , and/or participation drug clinical study within 6 month prior screen . 14 . Use immunosuppressive ( include Mitoxantrone ( Novantrone® ) cytotoxic agent within 6 month prior screen visit . 15 . Previous use either following : natalizumab ( Tysabri® ) , cladribine laquinimod . 16 . Previous treatment glatiramer acetate ( Copaxone® ) IVIG within 3 month prior screen visit . 17 . Previous treatment Interferon beta1a ( Avonex® Rebif® ) Interferon beta1b ( Betaseron® ) . 18 . Systemic corticosteroid treatment ≥30 consecutive day duration within 2 month prior screen visit . 19 . Previous total body irradiation total lymphoid irradiation . 20 . Previous stemcell treatment , autologous bone marrow transplantation allogenic bone marrow transplantation . 21 . A known history tuberculosis . 22 . Acute infection 2 week prior baseline visit . 23 . Major trauma surgery 2 week prior baseline visit . 24 . A history vascular thrombosis ( exclude cathetersite superficial venous thrombophlebitis ) . 25 . A carrier state factor V Leiden mutation ( either homo heterozygous ) history disclose screening . 26 . Positive screen test Hepatitis B surface antigen , Hepatitis C antibody , HIV antibody disclose screen visit . 27 . Use potent inhibitor CYP3A4 within 2 week prior baseline visit ( see detailed list drug protocol ) ( 1 month fluoxetine ) . 28 . Use amiodarone within 2 year prior screen visit . 29 . Pregnancy breastfeed . 30 . Subjects clinically significant unstable medical surgical condition would preclude safe complete study participation , determine medical history , physical examination , ECG , laboratory test chest Xray . Such condition may include : A cardiovascular pulmonary disorder wellcontrolled standard treatment permit study protocol . A gastrointestinal disorder may affect absorption study medication . Renal , metabolic , endocrinological hematological disease . Any form chronic liver disease , include know nonalcoholic steatohepatitis . A ≥2xULN serum elevation either follow screening : ALT , AST direct bilirubin . A QTc interval ( obtain either two ECG recording screen mean value calculate three measurement baseline visit ) ≥450msec . A family history LongQT syndrome . A history drug and/or alcohol abuse . Major psychiatric disorder . A history convulsive disorder . Known hypersensitivity either following : mannitol , meglumine sodium stearyl fumarate . Known hypersensitivity would preclude administration laquinimod . 31 . The subject 's inability give inform consent , complete study , subject consider investigator , reason , unsuitable candidate study . 32 . A known history sensitivity Gadolinium . 33 . Inability successfully undergo MRI scanning . 34 . A known history hypersensitivity natural recombinant interferon beta , human albumin , component formulation Avonex® . 1 . Subjects suffer form progressive MS 2 . Any condition investigator feel may interfere participation study 3 . Subjects clinically significant unstable medical surgical condition would preclude safe complete study participation 4 . Subjects receive investigational medication , immunosuppressives cytotoxic agent within 6 month prior screen 5 . Previous treatment immunomodulators within two month prior screen 6 . Pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>